Ustekinumab – a new biologic drug for the treatment of Crohn’s disease

Česká verzia

Authors: M. Lukáš
Authors place of work: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in the journal: Gastroent Hepatol 2017; 71(1): 36-39
Category:
doi: https://doi.org/10.14735/amgh201736

Zdroje

1. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016; 375(20): 1946– 1960.

2. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab a human interleukin 12/ 23 monoclonal antibody in patients with moderate to severe Crohn’s disease. Gastroenterology 2008; 135(4): 1130– 1141. doi: 10.1053/ j.gastro.2008.07.014.

3. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367(16): 1519– 1528. doi: 10.1056/ NEJMoa1203572.

4. Battat R, Kopylov U, Bessissow T et al. Association of ustekinumab trough concentration with clinical, biochemical and endoscopic outcome. Presented at: 11th Congress of ECCO, Amsterdam 2016.

5. Verstockt B, Van Assche G, Vermiere Set al. Biological therapy targeting the IL-23/ IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther 2017; 17(1): 31– 47.

6. Deepak P, Loftus EV Jr. Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy. Drug Des Devel Ther 2016; 10: 3685– 3698.

7. Rutgeerts P, Gasink C, Blank M et al. A multicenter, double-blind, placebo--controlled phase 3 study of ustekinumab, a human IL-12/ 23p40 monoclonal antibody, in moderate-severe Crohn’s disease refractory to anti-TNFα: UNITI-1. Presented at: 11th Congress of ECCO, Amsterdam 2016.

8. Feagan B, Gasink C, Lang Y et al. A multicenter, randomized, double-blind, placebo-controlled phase 3 study of ustekinumab, a human monoclonal antibody to IL-12/ 23p40, in patients with moderately to severely active Crohn’s disease who are naive or not refractory to anti-TNFα: results from the UNITI-2 study. Presented at: ACG 2015.

9. Sandborn W, Feagan BG, Gasink C et al. A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate – severe Crohn’s disease patients: results from IM-UNITI. Gastroenterology 2016; 150 (4 Suppl 1): S157– S158. Abstract 768.